Replies to post #832 on Ariad Pharmaceuticals Inc fka ARIA

[DonShimoda]

You need to go back and listen to the conference call if it is still online.

Actually, DewDiligence has it right. Here's the exact quote from MRK's R&D presentation in May.

Next slide. Let me now move on to oncology with our mTOR inhibitor, ridaforolimus -- or MK-8669.
Our oncology pipeline, as you know, is relatively young, but it's developing nicely. I'm pleased to say that our mTOR inhibitor
is moving along well, and we anticipate filing it for soft tissue sarcoma this year, pending the results of an interim analysis.